Alvotech (ALVOW)Luxembourg, Luxembourg | NasdaqGM
0.49 USD
|
Hot Take ↕ | Aug. 22, 2026, 3:47 a.m. EDT
The immediate outlook is severely bearish as the stock has just collapsed from $0.33 to $0.22 in less than a month, testing crucial support levels while trading near its 52-week low. This sharp decline suggests a breakdown in the technical structure, making a near-term bounce unlikely without significant volume or catalysts. Looking further ahead, the business fundamentals are deteriorating rapidly with revenue contracting by nearly 39% and the company burning through cash, evidenced by negative free cash flow and operating cash flow. The balance sheet is precarious, carrying debt significantly higher than its cash reserves, which creates a looming solvency risk. Furthermore, there is no dividend history to speak of, offering no income buffer for investors. With no analyst recommendations and a lack of price history to confirm a recovery trend, the investment case is currently non-existent. |
| Attribute | Value |
|---|---|
| Revenue per Share | 1.675 |
| Beta | 0.18 |
| Profit Margins | -36.31% |
| Website | https://www.alvotech.com |
| Attribute | Value |
|---|---|
| Address1 | 9, Rue de Bitbourg |
| Ask | 1.3 |
| Ask Size | 2 |
| Beta | 0.181 |
| Bid | 1.24 |
| Bid Size | 1 |
| Book Value | -0.537 |
| City | Luxembourg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Luxembourg |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.49 |
| Current Ratio | 1.646 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.49 |
| Day Low | 0.3799 |
| Ebitda | 75,733,000 |
| Ebitda Margins | 0.15312 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.49 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.3799 |
| Fifty Two Week Low Change | 0.1101 |
| Fifty Two Week Low Change Percent | 0.2898131 |
| Fifty Two Week Range | 0.3799 - 0.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 140,789,299 |
| Free Cashflow | -123,130,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,279 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.49 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.60662 |
| Gross Profits | 300,038,016 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,022-06-16 |
| Language | en-US |
| Long Business Summary | Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. |
| Long Name | Alvotech |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_693209405 |
| Net Income To Common | -179,590,000 |
| Open | 1.52 |
| Operating Cashflow | -198,702,000 |
| Operating Margins | -0.11052 |
| Previous Close | 0.49 |
| Price Hint | 4 |
| Price To Book | -0.9124767 |
| Profit Margins | -0.36310002 |
| Quick Ratio | 0.793 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.49 |
| Regular Market Day Low | 0.3799 |
| Regular Market Day Range | 0.3799 - 0.49 |
| Regular Market Open | 1.52 |
| Regular Market Previous Close | 0.49 |
| Regular Market Price | 0.49 |
| Regular Market Time | 1,787,674,013 |
| Regular Market Volume | 101 |
| Return On Assets | 0.02187 |
| Revenue Growth | -0.389 |
| Revenue Per Share | 1.675 |
| Sand P52 Week Change | 0.20504117 |
| Sector | |
| Sector Key | |
| Short Name | Alvotech Warrant |
| Source Interval | 15 |
| Symbol | ALVOW |
| Total Cash | 142,750,000 |
| Total Cash Per Share | 0.4 |
| Total Debt | 1,451,784,960 |
| Total Revenue | 494,608,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 101 |
| Website | https://www.alvotech.com |
| Zip | 1,273 |